Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
about
Outcomes of localized prostate cancer following conservative managementSurvival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancerImpact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Cucurbitacin E induces apoptosis of human prostate cancer cells via cofilin-1 and mTORC1Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancerPrevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.Testosterone regulates tight junction proteins and influences prostatic autoimmune responsesRisk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.Influence of gallate esterification on the activity of procyanidin B2 in androgen-dependent human prostate carcinoma LNCaP cells.Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study.Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate CancerDoes primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?An economic analysis of conservative management versus active treatment for men with localized prostate cancerObesity, energy balance, and cancer: new opportunities for preventionSurvival following primary androgen deprivation therapy among men with localized prostate cancerEffectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.Contemporary treatment of high-risk localized prostate cancer.Low-dose diethylstilbestrol for the treatment of advanced prostate cancerHigh-intensity focused ultrasound therapy for prostate cancer.Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer.The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population.Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy.External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients.The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer.Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignanciesDownregulation of cytochrome P450scc as an initial adverse effect of adult exposure to diethylstilbestrol on testicular steroidogenesis.Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy.Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden.Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.Markers of Prostate Cancer: The Role of Circulating Tumor Markers in the Management of Bone Metastases
P2860
Q24647380-54F02805-C1CD-4823-B6EE-E378DDC39A23Q33304413-91945A27-B83F-4F1C-AAF4-99B49FF4CDA7Q33351115-87B80392-9D2A-4D16-B53C-CF972CA18B25Q33526534-A5BF4A8D-9ED2-443D-BC5A-EA10EEE9D903Q33566395-3CD0E9D9-57A8-4264-8EE0-C2684FF554A9Q33751257-A005ACE4-5939-43C3-9332-3C00AADEB464Q33877542-B8E9D78C-15A4-49F1-B133-E7503AFB4372Q33926384-A4DBC4DE-E026-47F2-AEB0-27AE74153AA5Q33962057-163A9939-973A-49FC-9A1C-25D847E24A58Q34366865-7C008BF4-BEC1-4280-B10E-317D4C7DF154Q34400210-BBCFC3F4-517B-4CD4-B249-DE246752BA17Q34984105-12AB48E5-C8D4-4CD3-B2CD-68393C9ECD57Q35433102-AC586E8A-4DD3-4B58-B407-A4E088637C9BQ36075018-88497819-13E3-43C6-A45A-98446F398610Q36319986-B96D1052-E5E7-4277-A286-6C0ABC49E956Q36520468-0F629BC7-977A-4935-A5ED-F92862134DFCQ36810924-032F0FC0-2DEE-44B3-8863-86414B6A41D1Q37104386-E13E1AC7-3B96-4B34-BBBD-8AB92FAFD450Q37712068-DB0107FF-165E-4887-B977-83D0A9AAD46FQ37774353-3C7B9B98-5394-4E26-A956-48F99892596BQ37906889-47D6F80C-AC04-49DB-8906-3381D632CCA0Q37970412-480C17B7-60D7-44FE-A6E7-926DE9D3E38EQ37996104-679D977A-4E30-4BBC-A4E5-F9EB37084810Q38063121-735B0B09-0E83-4993-A681-206D6EE7D9A2Q38208193-6BB7C448-5D26-4227-981D-6D115BB0B354Q38399583-1E2DAB48-64E3-437E-BFE6-C5EE77124A2AQ38815680-0B64D240-8ADA-41A8-895C-6F19BD7B7AF0Q38822554-1D7044A1-6515-4789-ADEB-318513BDBE60Q41430910-1DCD4E3F-0DF3-425A-9B53-830889AE3903Q42578251-DCEB2D3C-889E-4CBF-86D6-7828744386DDQ42710193-79685FC1-202D-470E-9E9A-666D87F52F88Q43723219-1CECE72F-14F3-485B-A3EF-842D09854540Q44187033-080ADC73-F0A4-4520-8F62-A920679E73D5Q44833341-CDF8B8E0-415C-47C1-B1F0-AC7BB17B065FQ46015267-5637393D-451A-402C-8B6A-F6E499818B81Q51739623-7B9FE655-FF53-48CD-9C09-C79F7E669985Q58487854-8B33D3B6-55F4-4795-BD92-7268DF769066
P2860
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Androgen-deprivation therapy a ...... c Research Endeavor (CaPSURE).
@ast
Androgen-deprivation therapy a ...... c Research Endeavor (CaPSURE).
@en
type
label
Androgen-deprivation therapy a ...... c Research Endeavor (CaPSURE).
@ast
Androgen-deprivation therapy a ...... c Research Endeavor (CaPSURE).
@en
prefLabel
Androgen-deprivation therapy a ...... c Research Endeavor (CaPSURE).
@ast
Androgen-deprivation therapy a ...... c Research Endeavor (CaPSURE).
@en
P2093
P356
P1433
P1476
Androgen-deprivation therapy a ...... c Research Endeavor (CaPSURE).
@en
P2093
CaPSURE Investigators
Eric P Elkin
Janeen DuChane
Janet E Cowan
Jun Kawakami
Peter R Carroll
P304
P356
10.1002/CNCR.21799
P407
P577
2006-04-01T00:00:00Z